Press release
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung - Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung\n\n\n- Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing\n\n\n- Promising Preclinical Data Across Multiple Gene Targets Suggest Potentially Broad Applications for Arrowhead’s TRiM™ Platform\n\n\n PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy. In an ongoing Phase 1/2 clinical trial, ARO-RAGE, Arrowhead’s investigational RNAi therapeutic for the treatment of inflammatory lung diseases, achieved mean target gene knockdown of up to 90% with a maximum of 95% after a single inhaled administration.\n\n\nInterim results from the healthy volunteer portion of the ARORAGE-1001 Phase 1/2 clinical trial show that ARO-RAGE reduced soluble RAGE (sRAGE) concentration in bronchoalveolar lavage fluid (BALF) and serum in a dose-dependent manner. Reduction of serum sRAGE was similar in healthy volunteers and in patients with asthma at the 44 mg dose level. Additional dose cohorts are ongoing. Based on interim blinded safety results from the ongoing study, ARO-RAGE has been well-tolerated to date in healthy volunteers and asthma patients.\n\n\n“Today we announced additional data on multiple programs from our emerging pipeline of first-in-class pulmonary targeted RNAi therapeutic candidates at the European Respiratory Society International Congress. Clinical results from the ARO-RAGE Phase 1/2 study are highly encouraging and demonstrate a significant level of target gene knockdown with a duration of effect that may enable a long dosing interval possibly up to once every two months,” said Javier San Martin, M.D., chief medical officer at Arrowhead. “In addition, the preclinical data presented at ERS suggest that the TRiM™ platform can achieve compelling results across multiple additional gene targets in the lung, including MUC5AC, MMP7, and our newest program against thymic stromal lymphopoietin (TSLP), a clinically well validated target.”\n\n\nArrowhead Abstracts at ERS 2023\n\n\nA Clinical-Stage Inhaled RNAi Therapeutic for Pulm...